Blue Jet Q1 PAT falls 14% YoY to ₹78 Cr as revenue slips 17% off high base; margins hold

Blue Jet Healthcare opened FY27 with a year-on-year decline: standalone revenue from operations of ₹293.11 Cr fell 17.4% against a strong ₹354.76 Cr in Q1 FY26, and net profit of ₹78.26 Cr was down 14.2% from ₹91.17 Cr. The optics are far better sequentially — revenue up 24.9% and PAT up 21.6% over a soft Q4 FY26 — but the year-ago base is the primary read, and on that measure the quarter is a step down for a company management had positioned for a "commercialization and growth cycle" in FY27.

Margins were the redeeming feature: net margin held at ~25.4% of total income (vs ~25.1% a year ago), and gross material cost eased to ~47% of sales (from ~52%), even as reported cost of materials jumped on a ₹41.77 Cr inventory build. Operating margin at ~33.5% slipped only marginally from 34.1% YoY, while other income of ₹15.24 Cr (up from ₹8.25 Cr) cushioned the bottom line. So this is a topline-and-volume problem, not a profitability one — the single reportable segment (sweeteners, contrast media intermediates, pharma intermediates/APIs) simply did less business than in a bumper year-ago quarter, with the PI/API normalisation management flagged not yet visible in the print.

The stock went into the print at ₹586.65, up 5.3% over the past month of trading.

For context: PAT has now risen for 2 consecutive quarters.

Single reportable segment — no subsidiaries, so no consolidated accounts prepared

The result sits awkwardly against expectations. Street consensus embeds ~23% revenue and ~21% profit growth for full-year FY27 (Trendlyne, 5 analysts), and management's own last-call guidance was for double-digit contrast-media growth plus PI/API recovery beyond FY25 peaks — a 17% YoY revenue decline in Q1 is a soft start against both, implying heavy H2 back-loading is now required. On corporate actions the quarter was busy: the board declared a ₹1.2/share (60%) FY26 dividend (record date Sep 14), re-appointed Executive Chairman Akshay Arora and MD Shiven Arora for five-year terms (Apr 2027–2032) and reappointed auditor KKC, and — just after quarter-end — closed an ₹800 Cr QIP at ₹506/share (1.58 Cr new shares) earmarked for the Vizag greenfield and Mahad completion. That raise strengthens the balance sheet for the promised capex cycle but will dilute EPS (already ₹4.51 vs ₹5.26 YoY) until the new capacity contributes.